BETA: Please send your feedback!
Jazz Pharmaceuticals
JAZZ:NAS
Pharmaceuticals: Other
—
MID cap
(—)
—
since start of 2020
—
About
Pharmaceuticals: Other
Founded 2012
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd on January 18, 2012 and is headquartered in Dublin, Ireland.
website
Headquarters
Executives
| Name | Title | Gender |
| Bruce C. Cozadd, MBA | Chairman & Chief Executive Officer | Male |
| Katherine A. Littrell, PhD | Vice President-Investor Relations | Female |
| Suzanne Sawochka Hooper | Executive Vice President & General Counsel | Female |
| Heather McGaughey | Senior Vice President-Human Resources | Female |
| Russell J. Cox | Chief Operating Officer & Executive Vice President | Male |
| Matthew P. Young, MBA | Chief Financial Officer & Executive Vice President | Male |
| Karen L. Smith, MD, PhD | Chief Medical Officer, Global Head-R&D | Female |
Mindful Investing Summary
Jazz Pharmaceuticals - Competitors and Related Companies
How Jazz Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Jazz Pharmaceuticals
JAZZ:NAS
Pharmaceuticals: Other
—
MID cap
(—)
—
since start of 2020
—
Valeant Pharmaceuticals International
VRX:NYS
Pharmaceuticals: Other
—
MID cap
(—)
—
since start of 2020
—
AmerisourceBergen
ABC:NYS
Medical Distributors
—
LARGE cap
(—)
—
since start of 2020
—
Endo International
ENDP:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2020
—
Teva Pharmaceutical Industries
TEVA-IL:TAE
Pharmaceuticals: Generic
—
LARGE cap
(—)
—
since start of 2020
—
Novartis
NOVN-CH:SWX
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—